Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Akebia Therapeutics (AKBA) Discloses $50M ATM Offering
August 11, 2015 4:28 PM EDTAkebia Therapeutics (NASDAQ: AKBA) filed a prospectus supplement with the Securities and Exchange Commission that contemplates the sale of up to $50 million of shares of the Companys common stock, $0.00001 par value per share, from time to time in at-the-market offerings pursuant to a... More
